Literature DB >> 29303062

The Role of Microsatellite Instability in Positive Margin Gastric Cancer Patients.

Karol Polom1,2, Daniele Marrelli1, Elizabeth C Smyth3, Costantino Voglino1, Giandomenico Roviello4,5, Valeria Pascale1, Julian Varas6, Carla Vindigni7, Franco Roviello1.   

Abstract

PURPOSE: A positive resection margin (RM+) is acknowledged as a poor prognostic factor after gastrectomy. Microsatellite instability (MSI-H) gastric cancer has been identified as a subgroup of gastric cancer that may be associated with an improved prognosis. The aim of the study was an analysis of MSI status on patients with margin involvement after gastrectomy and examination of the association between MSI, margin status, and survival outcomes.
METHODS: From a large prospectively annotated surgical database we collected clinicopathological and survival data on patients who had undergone a potentially curative resection for gastric cancer. MSI status was assessed using a standard 5-marker quasi-monomorphic mononucleotide repeat panel. Patients who were R+ and either microsatellite stable (MSS) or MSI-H were identified and clinicopathological characteristics and disease specific survival was compared.
RESULTS: Three hundred and eighty-six patients were identified; 102 (26.4%) cancers were MSI-H. The proportion of R+ resections was not significantly different in MSS and MSI-H groups. For MSS patients 3-, 5-, and 10-year disease-specific survival rates were 9.1%, 0%, and 0%, respectively; for patients with MSI-H R+ tumors these were 38.5%, 30.8%, and 15.4%, respectively. In Cox analysis MSI-H, female gender, and T ≥3 were significantly associated with survival.
CONCLUSIONS: Patients with MSI-H gastric cancer may have long-term survival despite R+ margin status. The molecular division of gastric cancer may be an important step in identifying possible tailored surgical treatments corresponding to clinical and pathological factors.

Entities:  

Keywords:  mismatch repair genes; molecular; stomach cancer; surgery

Mesh:

Year:  2018        PMID: 29303062     DOI: 10.1177/1553350617751461

Source DB:  PubMed          Journal:  Surg Innov        ISSN: 1553-3506            Impact factor:   2.058


  6 in total

Review 1.  MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy.

Authors:  Maria Grazia Rodriquenz; Giandomenico Roviello; Alberto D'Angelo; Daniele Lavacchi; Franco Roviello; Karol Polom
Journal:  J Clin Med       Date:  2020-05-11       Impact factor: 4.241

Review 2.  Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches.

Authors:  Margherita Ratti; Andrea Lampis; Jens C Hahne; Rodolfo Passalacqua; Nicola Valeri
Journal:  Cell Mol Life Sci       Date:  2018-09-01       Impact factor: 9.261

3.  Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications.

Authors:  Carolina Martinez-Ciarpaglini; Tania Fleitas-Kanonnikoff; Valentina Gambardella; Marta Llorca; Cristina Mongort; Regina Mengual; Gema Nieto; Lara Navarro; Marisol Huerta; Susana Rosello; Desamparados Roda; Noelia Tarazona; Samuel Navarro; Gloria Ribas; Andrés Cervantes
Journal:  ESMO Open       Date:  2019-05-27

Review 4.  DNA Damage Repair and Current Therapeutic Approaches in Gastric Cancer: A Comprehensive Review.

Authors:  Menghui Wang; Chuan Xie
Journal:  Front Genet       Date:  2022-08-12       Impact factor: 4.772

Review 5.  The Pattern of Signatures in Gastric Cancer Prognosis.

Authors:  Julita Machlowska; Ryszard Maciejewski; Robert Sitarz
Journal:  Int J Mol Sci       Date:  2018-06-04       Impact factor: 5.923

Review 6.  Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies.

Authors:  Julita Machlowska; Jacek Baj; Monika Sitarz; Ryszard Maciejewski; Robert Sitarz
Journal:  Int J Mol Sci       Date:  2020-06-04       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.